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Coxiella burnetii, the causative agent of Q fever, is a Gram-negative intracellular bacterium
transmitted via aerosol. Regulatory approval of the Australian whole-cell vaccine Q-VAX®
in the US and Europe is hindered by reactogenicity in previously exposed individuals.
The aim of this study was to identify and rationally select C. burnetii epitopes for
design of a safe, effective, and less reactogenic T-cell targeted human Q fever vaccine.
Immunoinformatic methods were used to predict 65 HLA class I epitopes and 50
promiscuous HLA class II C. burnetii epitope clusters, which are conserved across
strains of C. burnetii. HLA binding assays confirmed 89% of class I and 75% of class II
predictions, and 11 HLA class II epitopes elicited IFNγ responses following heterologous
DNA/DNA/peptide/peptide prime-boost immunizations of HLA-DR3 transgenic mice.
Human immune responses to the predicted epitopes were characterized in individuals
naturally exposed to C. burnetii during the 2007–2010 Dutch Q fever outbreak. Subjects
were divided into three groups: controls with no immunological evidence of previous
infection and individuals with responses to heat-killed C. burnetii in a whole blood IFNγ
release assay (IGRA) who remained asymptomatic or who experienced clinical Q fever
during the outbreak. Recall responses to C. burnetii epitopes were assessed by cultured
IFNγ ELISpot. While HLA class I epitope responses were sparse in this cohort, we
identified 21 HLA class II epitopes that recalled T-cell IFNγ responses in 10–28% of
IGRA+ subjects. IGRA+ individuals with past asymptomatic and symptomaticC. burnetii
infection showed a comparable response pattern and cumulative peptide response
which correlated with IGRA responses. None of the peptides elicited reactogenicity
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in a C. burnetii exposure-primed guinea pig model. These data demonstrate that a
substantial proportion of immunoinformatically identified HLA class II epitopes show
long-lived immunoreactivity in naturally infected individuals, making them desirable
candidates for a novel human multi-epitope Q fever vaccine.
Keywords: Coxiella burnetii, Q fever, multi-epitope vaccine, immunoinformatics, IFNγ, T cell
INTRODUCTION
Q fever is a zoonotic disease that is transmitted to humans
predominantly by aerosol from infected ruminants such as goats,
sheep, and cattle and has a global public health impact (1). Its
causative agent, the small Gram-negative coccobacillus Coxiella
burnetii, infects a wide range of vertebrate and invertebrate
hosts, is very stable in the environment and highly contagious;
it is estimated that a single inhaled organism can result in
infection (2). As a result, C. burnetii is also considered to
be a potential biothreat agent (3). Q fever is endemic in
many countries worldwide, with outbreaks occurring mainly
in occupational settings, including the livestock industry and
deployed military personnel (1). The largest reported outbreak
occurred in the Netherlands from 2007 to 2010 with an estimated
40,000 infections at the center of the epidemic area alone (4).
Infection remains asymptomatic in an estimated 50–60% of
individuals (1). Acute C. burnetii infection, when identified
clinically and serologically, can be treated with antibiotics such as
doxycycline. However, long-term complications of infection are
common; 10–20% of patients with acute Q fever later develop Q
fever fatigue syndrome, and 1–5% of (often asymptomatically)
infected individuals progress to persistent infection known as
chronic Q fever, manifesting as endocarditis, aneurysms or
vascular infections in individuals with specific risk factors (1, 5).
Therefore, a preventive Q fever vaccine is considered critical in
occupational and biodefense settings (6).
The two currently available Q fever vaccine formulations,
Q-VAX R© for humans (licensed for use in Australia only) and
COXEVAC R© for ruminant animals such as goats (licensed in
the European Union), are inactivated whole cell vaccines based
on phase I C. burnetii. Although Q-VAX R© is strongly protective
(7, 8), reported side effects in previously exposed individuals,
in particular at the site of injection, necessitate pre-vaccination
screening and are a daunting hurdle to regulatory approval in
the US and Europe (6, 9). Hence, there is a clear need for
a less reactogenic and at least equally efficacious vaccine for
occupational and biodefense purposes.
Subunit vaccines have the advantage over traditional whole
cell vaccines that they are better tolerated and offer the
opportunity for rational design, both in terms of the target
antigens and the appropriate delivery or adjuvant system
selected to elicit the desired immune response (10). While both
humoral and cellular immune responses are elicited upon C.
burnetii infection and administration of whole cell vaccines
(11), antibodies alone are insufficient to resolve infection (12,
13). Results from studies in murine infection models suggest
that T-cell responses, particularly Th1 responses, are critical
for clearance of the bacteria (13–15). The Th1 cytokine IFNγ
has been shown to restore phagosome maturation and facilitate
intracellular killing of C. burnetii (16, 17). Accordingly, a proof
of concept study showed that partial protection in C57BL/6 mice
can be elicited by a vaccine comprising seven C. burnetii CD4
epitopes (18).
In this context, the objective of the Q-VaxCelerate consortium
is to develop a non-reactogenic T-cell-targeted vaccine to
prevent Q fever disease in humans (19). To rationally
select epitopes for inclusion in such a vaccine, we set out
to identify HLA class I and class II C. burnetii epitopes
using a combination of immunoinformatic and experimental
methods. A library of computationally predicted human T-cell
epitopes derived from C. burnetii was assessed for human
HLA binding in vitro, immunogenicity and reactogenicity
were determined in animal models, and antigenicity was
investigated in a cohort of individuals naturally exposed to
C. burnetii during the 2007–2010 Dutch Q fever outbreak.
Using this systematic approach, we successfully identified a
set of epitopes that recalls long-term memory IFNγ T-cell
responses in humans and thus represents a promising first




Animal research protocols for studies with HLA-DR3 transgenic
mice performed by EpiVax were reviewed and approved
by TGA Sciences Incorporated Institutional Animal Care
and Use Committee (P07-10R20-EV69, P07-10R20-EV71).
Animal research protocols for guinea pig experiments were
reviewed and approved by the Colorado State University
Institutional Animal Care and Use Committee (14-5305A, 16-
6844A). All animal experimental activities were conducted
in full compliance with university, federal and international
regulations and the standards of the DoD Animal Care
and Use Review Office. Methods of euthanasia as described
below were consistent with the recommendations of the
Panel on Euthanasia of the American Veterinary Medical
Association (AVMA).
The human study was carried out in accordance with the
recommendations of the Medical Ethical Committee Brabant
(Tilburg, Netherlands). All subjects gave written informed
consent in accordance with the Declaration of Helsinki. The
protocol was reviewed and approved by the Medical Ethical
Committee Brabant (Tilburg, Netherlands, NL51305.028.15).
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Immunoinformatics
Sequence Collection
C. burnetii antigens used in epitope predictions were immune-
dominant antigens that were recognized by sera from C. burnetii-
exposed humans and demonstrated to stimulate CD4+ T-cell
and/or antibody responses in mice, as reported in the literature
(18, 20–29), and type IV secretion system (T4SS) effectors (21,
23, 30–37). Of 94 T4SS protein sequences retrieved from the
UniProt database (38), 53 were selected for immunoinformatic
analysis; 20 putative effectors lacking experimental support for
secretion, eight hypothetical proteins from pseudogenes and
13 proteins with discontinued database records were rejected.
An additional 40 sequences were retrieved from UniProt for
the immune-dominant antigen set. All sequences were retrieved
from the reference RSA 493/Nine Mile phase I C. burnetii strain.
Six additional complete C. burnetii genomes available in 2015
were obtained from UniProt for homology analyses: (i) RSA
331/Henzerling II, (ii) CbuK_Q154, (iii) Namibia, (iv) MSUGoat
Q177, (v) CbuG_Q212, and (vi) Dugway 5J108-111. Of note,
genome sequences were completed for two C. burnetii strains
associated with the Dutch Q fever outbreak (39) during the
course of this work, and all but one of the selected epitopes (p69)
were 100% conserved in the two Dutch strains.
Epitope Prediction
Sequences for all antigens from the reference Nine Mile strain
were scored for binding potential against a panel of HLA
class II and class I alleles using the EpiMatrix algorithm
(40). This algorithm as well as the ClustiMer and JanusMatrix
algorithms discussed below are part of the proprietary iVAX
toolkit developed by EpiVax, which is available for use under
license or by collaboration (http://epivax.com/immunogenicity-
screening/ivax-web-based-vaccine-design). Epitopes which were
100% identical in the corresponding antigens from at least six of
the seven genomes (HLA class I epitopes) or all seven genomes
(HLA class II epitopes) were prioritized. Class II epitopes
were identified for eight supertype HLA-DR alleles: DRB1∗0101,
DRB1∗0301, DRB1∗0401, DRB1∗0701, DRB1∗0801, DRB1∗1101,
DRB1∗1301, and DRB1∗1501. For class I epitopes, selections
were made based on predictions for six HLA-A and HLA-B
supertype alleles: A∗0101, A∗0201, A∗0301, A∗2402, B∗0702,
B∗4403. Each set of supertype alleles covers >95% of the human
population worldwide (41, 42). EpiMatrix assigns a score for
each peptide/allele pair on a normalized Z-scale. Peptides with Z-
Scores≥1.64 are considered hits and have a significant likelihood
of binding to HLA molecules. These sequences represent the top
5% of any randomly generated set of 9-mer peptides (43).
Regions of high class II epitope density per antigen were
identified using the ClustiMer algorithm for selection of vaccine
candidates with increased breadth of reactivity (40). ClustiMer
searches for contiguous segments of 15–30 amino acids with
elevated class II HLA binding promiscuity. Epitope density
within a cluster is estimated by EpiMatrix Cluster Scores, where
scores of 10 and above are considered elevated. Peptide sequences
with elevated EpiMatrix Cluster Scores usually contain class II
HLA bindingmotifs tomost, if not all, HLA-DR supertype alleles.
MHC Class II epitope clusters were further filtered to remove
sequences derived from signal sequences and transmembrane
domains to avoid peptide synthesis and solubility complications.
For class I peptides, epitopes with Z-Scores in the top 1% of a
normal distribution (Z-Score ≥2.32) were prioritized. A greater
weight was given to the top 1% EpiMatrix scoring peptides per
HLA class I supertype that were also predicted to bind to at least
one additional HLA class I supertype.
Homology Analysis
To eliminate peptide candidates unlikely to stimulate effector
T-cell responses due to potential cross-reactivity with T-cells
previously trained on host or commensal antigens, predicted
HLA class I and class II Coxiella sequences were screened
for T-cell receptor-face homology against host and commensal
proteins using the JanusMatrix algorithm (44). Databases
comprising the UniProt reviewed human proteome (http://www.
uniprot.org/proteomes/UP000005640) and Human Microbiome
Project gut commensal proteomes were used. Epitopes with low
human or human microbiome JanusMatrix homology scores
were prioritized. The JanusMatrix human homology score cutoff
was 2, for both HLA class I and II, and the microbiome cutoff was
25 for HLA class I and 37 for HLA class II. JanusMatrix cutoffs are
defined such that only 5% of randomly generated HLA ligands
exceed the thresholds.
Peptide Synthesis
Five milligrams of peptide for each epitope selected as
defined above were prepared by Fmoc solid phase peptide
synthesis (Twentyfirst Century Biochemicals, Marlborough, MA,
United States) and HPLC purified to >90% purity (peak area).
The peptide mass was verified by ESI-MS (QSTAR XL Pro, Qo-
TOF) and the sequence of each peptide was verified by tandem
mass spectrometry (CID MSMS).
HLA Binding Assays
HLA Class II Binding Assay
A competition-based assay based on Steere et al. was employed
(45). In 96-well plates, non-biotinylated test peptides over a
three-log concentration range competed for binding to 50 nM
soluble class II molecules (Benaroya Institute, Seattle, WA)
against a biotinylated standard peptide at a fixed concentration
(25 nM) at 37◦C for 24 h to reach equilibrium. Class II
molecules were then captured on ELISA plates using pan
anti-class II antibodies (clone L243, anti-HLA-DR; Biolegend).
Plates were washed and incubated with DELFIA Europium-
labeled streptavidin (Perkin Elmer) for 1 h at room temperature.
DELFIA Europium activation buffer (Perkin Elmer) was added
to develop the plates for 15–20min at room temperature
before data acquisition on a Time Resolved Fluorescence (TRF)
plate reader. All assays were performed in triplicate. Binding
assays were performed for 8 alleles: DRB1∗0101, DRB1∗0301,
DRB1∗0401, DRB1∗0701, DRB1∗0801, DRB1∗1101, DRB1∗1301,
and DRB1∗1501. Dose-dependent binding data were fitted by
non-linear regression to calculate IC50 values for each peptide-
HLA allele pair (GraphPad Prism Version 7). Peptide binding
affinity was classified according to the following: very high
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(IC50 <0.1µM), high (IC50 0.1–1µM), moderate (IC50 1–
10µM) and low affinity (IC50 10–100µM). Epitopes with IC50
values too high to accurately measure under binding conditions
tested (>100µM) or with no dose-dependent responses were
considered non-binders.
HLA Class I Binding Assay
A competition-based assay based on fluorescence polarization,
where reference fluorescent-labeled peptide is incubated with
soluble HLA with or without competitor test peptides, was
performed according to Buchli et al. (46). Peptide binding over
a three-log concentration range was assessed for the A∗0101,
A∗0201, A∗0301, A∗2402, B∗0702, and B∗4402 alleles. The latter
was used to test B∗4403 predictions. A dose response curve
fit was obtained by non-linear regression to calculate IC50
values for each peptide-HLA allele pair. Binding strength was
classified according to IC50 value: high (<5µM), moderate (5–
50µM), low (50–1,000µM) or no affinity (>1,000µM or no
dose-dependent response).
Assessment of Class II Epitope
Immunogenicity in tgHLA-DR3 Mice
Multi-Epitope DNA Vaccine Engineering
Multi-epitope DNA vaccines were engineered by concatenating
epitope sequences to form five multi-epitope genes, each
containing 10 HLA class II epitopes. To avoid production of
neo-epitopes at epitope junctions, the VaxCAD algorithm was
used to arrange epitopes in an order that diminishes potential
junctional immunogenicity (40). Where re-ordering by VaxCAD
did not sufficiently reduce potential junctional immunogenicity,
Gly-Pro-Gly-Pro-Gly spacer sequences were engineered
between epitopes to further remove junctional epitopes.
Genes were synthesized by GeneArt and subcloned at pre-
determined flanking restriction sites downstream of the tissue
plasminogen activator leader sequence in pNTC8682-eRNA41H
(Nature Technology Corporation), a DNA vaccine vector that
accommodates FDA recommendations for construction of
plasmid DNA vaccines.
Plasmid DNA Vaccine Production
High purity plasmids for immunization were prepared by Nature
Technology Corporation, Inc. at research grade. Each plasmid
underwent quality control testing including spectrophotometric
concentration and A260/A280 ratio determination (1.97),
restriction digest analysis to assure the presence of the multi-
epitope genes, agarose gel electrophoresis determination of
residual host RNA and DNA (none detected), and quantitative
endotoxin testing (<2.0 EU/mg).
Peptide Vaccine Preparation
Peptides produced by twentyfirst Century Biochemicals
corresponding to epitopes in the DNA vaccines were formulated
in incomplete Freund’s adjuvant (IFA) with 10 µg each of
immunostimulatory CpG oligodeoxynucleotide 1826 (5′-
TCCATGACGTTCCTGACGTT-3′), muramyl dipeptide (MDP)
and CL097 (InvivoGen).
Mice
HLA-DR3 transgenic mice were obtained from Dr. Chella David
(MayoMedical School) under commercial license to EpiVax. The
mice express theHLA-DRA andDRB1∗0301 genes on a B.10-Ab0
mouse class II-negative background (47).
Vaccinations
Vaccine and placebo-treated mice (n = 3/group) were all
female and 6–8 weeks old at the start of heterologous
DNA/DNA/peptide/peptide prime-boost immunizations.
Epitopes were arranged into five groups of 10 epitopes in
generally descending order of EpiMatrix epitope cluster score as
follows: Group 1 (p9, p12, p14, p22, p27, p28, p31, p32, p45, p49),
group 2 (p3, p7, p8, p15, p16, p38, p39, p42, p44, p46), group 3
(p4, p10, p19, p20, p21, p23, p25, p34, p40, p48), group 4 (p1,
p2, p5, p6, p11, p13, p30, p36, p41, p47), group 5 (p17, p18, p24,
p26, p29, p33, p35, p37, p43, p50). DR3 epitope scores correlated
with cluster scores across the groups. DNA-prime vaccine was
administered to mice intramuscularly by electroporation using
the Ichor Medical Systems TriGrid platform with 20 µL of 10 µg
naked plasmid DNA in sterile PBS injected into the quadriceps
muscle. Mice received the DNA vaccine twice spaced by a
2-week interval. Two weeks later, they were boosted twice with
peptide vaccine at a 2-week interval. For peptide immunizations,
each mouse was administered 100 µl IFA emulsion (50 µg
peptide) subcutaneously by needle stick injection. Four weeks
after the final vaccination, tgHLA-DR3 mice were euthanized
by administration of ketamine/xylazine intraperitoneally at 4–5
times the anesthetic dose (ketamine 80–100 mg/kg; xylazine
8–10 mg/kg).
Ex vivo ELISpot Assay in Mouse Splenocytes
The frequency of epitope-specific splenocytes was determined
by IFNγ ELISpot assay using the colorimetric Mabtech
IFNγ ELISpot Kit with pre-coated plates according to the
manufacturer’s protocol. Washed splenocytes in RPMI 1640
(Gibco) supplemented with 10% fetal calf serum (FCS, Atlanta
Biologicals) were added at 2.5 × 105 cells per well. Individual
peptides were added at 10µg/ml in triplicate wells. Peptide
pools were added at 10µg/ml, equating to 1µg/ml per peptide.
Triplicate wells were stimulated with 2µg/ml Concanavalin
A (ConA; Sigma Aldrich) as a positive control, and six
replicate wells with medium containing 0.02% DMSO were
used for background determination. Raw spot counts were
recorded by ZellNet Consulting, Inc. using a Zeiss high-
resolution automated ELISpot reader system and companion
KS ELISpot software. Results were calculated as the average
number of spots in the peptide wells, adjusted to spots
per one million cells. A response in immunized mice was
considered positive if the number of averaged spots was (i)
at least twice as high as background (stimulation index ≥2),
(ii) >50 spot forming cells above background per million
splenocytes (1 response per 20,000 cells), and (iii) statistically
different (p < 0.05) from that of mock immunized mice by
Student’s t-test.
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Human Study Cohort
Q fever exposed individuals were recruited from a cohort
characterized in a previous large Q fever study conducted in
the village of Herpen, the Netherlands (48), which experienced
a high incidence of C. burnetii infection during the 2007–
2010 Q fever outbreak (49). All subjects had been tested
using a Q fever interferon-γ release assay (IGRA, Q-detect
TM
)
assay of cellular immunity during a previous study in which
80% of the adult population of Herpen were screened for
Q fever (48). Individuals were invited to participate in the
current study following preselection based on clinical history
(disease, comorbidities, and medication) as well as IGRA and
serological data generated during the previous study (48). To
maximize the potential to detect C. burnetii epitope-specific
T-cells, preference was given to donors with strong responses
to whole heat-killed C. burnetii in the IGRA and without
potentially confounding immune disorders. In addition, five
individuals with known past symptomatic Q fever consented to
participate. In total, 143 participants provided written informed
consent. IGRA responses were re-assessed upon inclusion in
October 2015. Volunteers who had no history of Q fever disease
(48) and scored negative by immunofluorescence assay (50)
as well as by IGRA in spring 2014 and upon inclusion into
the present study in autumn 2015 were allocated to control
group A (n = 26). Seven volunteers that were IGRA positive
in 2014 but did not meet positive scoring thresholds anymore
1.5 years later upon inclusion into the present study were
excluded from further analysis. The remaining 110 volunteers
that were positive by IGRA in both 2014 and 2015 were
subdivided based on past Q fever disease [either registered
(notified) in the national surveillance system, or self-reported]
into groups B (asymptomatic, n = 73) and C (symptomatic,
n= 37).
Whole Blood IFNγ Release Assay
(Q-DetectTM)
Whole lithium-heparin anti-coagulated blood was stimulated
with C. burnetii antigen (heat killed Cb02629, Wageningen
Bioveterinay Research, lot 14VRIM014) in 96-well polypropylene
plates (Greiner BioOne) by adding 180 µl blood to 20 µl
C. burnetii antigen diluted in phenol red-free RPMI
supplemented with Glutamax (2mM), Gentamycin (5µg/ml)
and sodium pyruvate (1mM, all ThermoFisher Scientific). A 1.5
% (v/v, final concentration) solution of PHA-M (ThermoFisher
Scientific), was added to separate wells as a positive control.
Medium only was added to the negative control wells. All
stimulations were performed in duplicate. After 22 ± 1 h whole
blood cultures were re-suspended and IFNγ concentrations
were assessed in whole blood by ELISA, using the IFNγ Pelipair
protocol (Sanquin) with minor modifications. The upper
detection limit of IGRA under these conditions is 1,050 pg/ml. A
subject was scored positive by IGRA if the C. burnetii-induced
IFNγ production was ≥16 pg/ml above background and
the ratio of the logarithmic value of background-subtracted
C. burnetii and PHA responses {(log[C. burnetii]–log[neg
control])/(log[PHA]-log[neg control])} was ≥0.4.
HLA Typing of Human Subjects
HLA typing was performed at the HLA laboratory at the
Laboratory of Translational Immunology at the UMC Utrecht,
the Netherlands. Genomic DNA was isolated from EDTA
anti-coagulated blood within 48 h upon collection using the
MagNA Pure Compact system (Roche Diagnostics). The DNA
samples were typed for HLA-A, -B (5′-UTR-3′UTR), and
-DRB1 (exon 2–3′-UTR) by Next Generation Sequencing
(NGS). Firstly, HLA target sequences were generated by long-
range PCR using the Qiagen LongRange PCR kit and HLA-
A, -B, and -DRB1 primers as described previously (51).
Library preparation was performed using the GenDX NGSgo R©-
LibrX and NGSgo R©-IndX kits following the manufacturers’
recommendations (GenDX). Pooled samples were sequenced
on an Illumina MiSeq by 2 × 250 paired end reading
using the MiSeq reagent kit v2 (500 cycles). Sequences were
analyzed with the NGSEngine software (GenDX). The resulting
HLA-A, HLA-B, and HLA-DRB1 alleles were assigned to
supertype families as defined by (42, 52) and/or based on
homology of the HLA binding pockets. For determining allelic
frequencies, donors homozygous for a given HLA allele were
counted once.
Cultured ELISpot Assay Screening of
Peptides in Human PBMCs
A combination of antigen-specific T-cell expansion culture
and enzyme-linked immune spot assay (cultured ELISpot) was
chosen as the primary assay for peptide screening, to achieve
high sensitivity for detecting low frequency antigen-specific T-
cell responses to C. burnetii peptides and facilitate detection of
central memory T-cells (53). The protocol was adapted from
Subbramanian et al. (54) and optimized at Innatoss using two
reference peptide pools of HLA class I and class II peptides of CEF
(Cytomegalovirus, Epstein-Barr virus, and influenza; JPT Peptide
Technologies). A comparison of three media showed that RPMI
medium supplemented with 10% FCS (HyClone) as a blocking
and culture medium gave the best signal to background ratio in
this ELISpot assay.
Antigen-Specific Expansion
PBMCs were isolated from lithium-heparin anti-coagulated
blood using Leukosep tubes prefilled with Ficoll (Greiner
BioOne) according to the manufacturer’s recommendations.
Isolated PBMCs were used for antigen-specific expansion
cultures at 5 × 106 cells per well in 48-well flat bottom plates
(Corning) in 150 µl complete RPMI (phenol red-free RPMI
supplemented with Glutamax (2mM), Gentamycin (5µg/ml),
sodium pyruvate (1mM, all Thermo Fisher Scientific) and 10%
fetal bovine serum (HyClone). Antigen-specific expansion was
performed using stimulation with pools of 10 peptides each (final
concentration 2µg/ml per peptide, 0.2% DMSO). On day 3 and 6
of culture, medium was refreshed by addition of an equal volume
of complete RPMI with recombinant human IL-2 (Immunotools,
final concentration 20 units/ml). On day 8, cells were harvested,
counted and individual peptide responses assessed by ELISpot.
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ELISpot Assay
MultiScreen IP filter plates (Merck Millipore) were pre-wetted
with 35% ethanol, coated overnight with IFNγ capture antibody
at the recommended concentration (Diaclone) in DPBS (Thermo
Fisher Scientific) and blocked for at least 60min with complete
RPMI prior to addition of cells for re-stimulation. For each
expansion culture, recovered cells were evenly distributed for
peptide re-stimulation, negative and positive controls. Based
on cell availability, a median of 38,000 cells per expansion
pool (interquartile range (IQR) 27,000–52,000) were plated per
replicate well. Assay wells were re-stimulated with each of
the 10 respective individual peptides in quadruplicate (final
concentration 2µg/ml per peptide, 0.02% DMSO). Control wells
were stimulated with either medium only (containing 0.02%
DMSO; eight replicates) or with Staphylococcus enterotoxin B
(SEB, final concentration 1µg/ml, Sigma Aldrich; quadruplicate
assays). After 20 h incubation at 37◦C, plates were washed,
and sequentially incubated with a biotinylated anti-human
IFNγ detection antibody and streptavidin-alkaline phosphatase
conjugate in DPBS/0.5% FCS and developed using BCIP-NBT
(all Diaclone) according to the manufacturer’s recommendation.
ELISpot plates were dried overnight, scanned on an AID Classic
reader system and analyzed using the AID ELISpot software v7.0
(both AIDDiagnostika GmbH). Spot forming units were counted
using identical settings for all plates and all counts were reviewed
and adjusted manually only where necessary to remove artifacts.
Data Analysis
To account for variation in background responses between
expansion cultures and donors following cytokine-assisted T-cell
expansion and to decrease the likelihood of detecting false
positive responses in plates with either high background (when
only considering an absolute difference to background) or low
background (when only considering a fold difference above
background), three combined threshold criteria were applied.
TABLE 1 | Summary of in silico HLA class II and I epitope identification.
HLA class II HLA class I
Sero-reactive T4SS substrates Sero-reactive
Source antigens 40 53 40




High Scoring for HLA
bindinga
153 1,710 1,945









cNo source antigen represented by more than two epitopes; five epitopes per antigen set
for each of the 6 major HLA class I supertypes.
Peptide re-stimulation responses were defined as positive when
they were (i) significantly higher than spot counts in matched
negative control wells from the same expansion culture by one-
way ANOVA with Holm-Šídák multiple comparison correction
post-hoc test, reached (ii) a stimulation index of at least 2 above
the matched negative control wells, and (iii) an absolute cut-off
of >10 SFU/well.
Guinea Pig Reactogenicity Against Class I
and II Peptides
Female Dunkin-Hartley guinea pigs were sensitized by intranasal
inoculation with 106 genome equivalents of C. burnetiiNineMile
strain or saline in 100 µL volume, as described previously (55).
Peptides were tested by intradermal challenge, delivered at day 42
post sensitization. HLA class II and I peptides were administered
in pools of five, with each peptide being tested twice in two
different pool preparations. Peptide pools were created with 2
µg of each peptide (10 µg peptide per pool in total) in 100 µL
saline with 1% DMSO. Challenge with 2 µg COXEVAC R© whole
cell vaccine (Ceva Sante Animale, Libourne, France) was used
as a positive control; negative controls consisted of saline or 1%
DMSO injections. On day 7, animals were anesthetized (ketamine
40 mg/kg and xylazine 5 mg/kg, i.p.) and euthanized with
beuthanasia (i.p.). Gross reactions were monitored daily and skin
biopsies obtained at day 7 post-challenge were fixed, sectioned,
and stained with hematoxylin and eosin. Histological reactions
were scored by an experimenter blinded to the treatment
group, using the criteria previously described (55). Briefly, a
score of 0 indicates no inflammation, 1 indicates localized
macrophage dominated inflammation, 2 macrophage dominated
inflammation with limited tissue infiltrations, 3 lymphocytic
inflammatory infiltrates extending into the deep dermis, 4
edema and increased pyogranulomatous inflammation extending
deep into the subcutis, and 5 widespread pyogranulomatous
inflammation including necrosis.
RESULTS
In silico Identification of Predicted
C. burnetii T-Cell Epitopes
Two C. burnetii antigen sets were selected as the basis for
immunoinformatic identification of HLA class I and II T-cell
epitopes. The first set (for HLA class I epitope prediction) was
comprised of 53 published substrates of the type IV secretion
system (T4SS), which are translocated fromC. burnetii to the host
cytoplasm where they are expected to enter the class I antigen
processing pathway and trigger CD8+ T cell responses (21, 23,
30–37). The second set (for both HLA class I and II epitope
prediction) covered 40 sero-reactive C. burnetii antigens based
on antibody responses in humans and mice, as well as evidence
of processing and presentation to stimulate murine CD4+ T-cells
(18, 26, 28, 29, 56). Using the EpiMatrix algorithm, 8,643 putative
9- and 10-mer T-cell epitopes predicted to bind to at least
one of six HLA class I supertype alleles and 282 promiscuous
epitope clusters, spanning 14–25 amino acids, predicted to bind
HLA class II alleles covering >90% of the world-wide human
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population, were identified from the reference C. burnetii Nine
Mile strain (Table 1).
The derived HLA class I epitopes and HLA class II
promiscuous epitope clusters were then filtered to focus on
sequences that (i) are conserved with other C. burnetii strains;
(ii) have very high likelihood of binding human HLA alleles;
(iii) exhibit low potential for cross-reactivity with peptides
derived from the human proteome or microbiome based on the
JanusMatrix algorithm (44); and (iv) do not present obvious
issues for peptide synthesis or stability. Finally, 50 HLA class II
epitope clusters (Table 2) and 65 HLA class I epitopes (Table 3)
were selected for immune reactivity screening such that no source
antigen was represented more than twice. Five epitopes were
selected for each of the six HLA class I supertypes and for
each antigen set (T4SS substrates and sero-reactive antigens),
if possible giving preference to HLA class I ligands predicted
to bind to at least two class I supertype alleles. An additional
five HLA class I epitopes were specifically selected from the
immunodominant C. burnetii antigen com1 (28, 56).
HLA Binding of Predicted C. burnetii
Epitopes
Epitope predictions were validated using HLA binding assays.
Peptides representing the 50 promiscuous C. burnetii HLA class
II epitope clusters were assayed in competition binding assays
against each of the eight class II HLA supertype alleles (Figure 1).
Each of the peptides bound as predicted to at least two HLA-
DR alleles: 6% bound to two HLA-DR alleles, 2% to three alleles,
10% to four alleles, 4% to five alleles, 28% to six alleles, 24% to
seven alleles, and 26% to all eight alleles. Independent of original
binding predictions, amongst all 400 peptide-allele pairs tested,
6.5% of peptides bound with very high affinity (IC50 <0.1µM),
16% of peptides bound with high affinity (IC50 0.1–1µM), 30%
bound with moderate affinity (IC50 1–10µM), 25.5% bound with
low affinity (IC50 10–100µM), and 22% exhibited no detectable
affinity for the HLA-DR tested (IC50 >100µM or no dose-
dependent response). Overall, 81% of predicted binding events
and 41% of predicted non-binding events were verified in vitro.
Collectively, the agreement of computational predictions with
binding assay results was 75% (χ2, p < 0.001), ranging from 60
to 88% for individual alleles (Table S1), consistent with published
studies using the same algorithms and assay conditions (57, 58).
HLA class I binding affinities were determined for the primary
predicted HLA-A/B supertype allele for each peptide (Figure 2).
Among the 65 peptide-allele pairs tested, 56% bound with
high affinity (IC50 <5µM), 21.5% with moderate affinity (IC50
5–50µM), 7.5% with low affinity (IC50 50–1,000µM), and 14%
exhibited no detectable affinity for the HLA class I allele tested
(IC50 >1,000µM or no dose-dependent response). All predicted
A∗0201, A∗0301, and A∗2402 peptides, and 8/11 A∗0101 and
B∗0702 peptides boundHLA as predicted. An assay using B∗4403
molecules was not available, but an assay using the related B∗4402
allele showed eight out of 11 B∗4403 peptides bound HLA as
predicted. Based on these results, epitope prediction accuracy was
100% for A∗0201, A∗0301, and A∗2402 and 73% for A∗0101,
B∗0702, and B∗4403. Overall, predictive accuracy for this set
of HLA class I peptides was 89% (Table S1). Taken together,
the binding assay results suggest that the predicted HLA class
II epitope clusters and HLA class I epitopes represent a set of
sequences with meaningful potential for stimulating C. burnetii-
specific immune responses across a broad range of HLA types.
Immunogenicity of Class II Epitopes in
tgHLA-DR3 Mice
While peptide binding to HLA is necessary to induce a
T-cell response, it is not sufficient. To determine whether
the predicted C. burnetii HLA class II epitope clusters are
capable of eliciting a de novo immune response via a cognate
human HLA in vivo, the class II peptides were screened for
immunogenicity in transgenic mice expressing humanHLA-DR3
(tgHLA-DR3). The 50 HLA class II C. burnetii peptides were
arranged into five groups of 10 peptides each based on predicted
HLA-DR3 immunogenicity and three mice per group were
subjected to heterologous DNA/DNA/peptide/peptide prime-
boost immunizations. Peptide-specific responses of splenocytes
from tgHLA-DR3 mice were assessed by ex vivo IFNγ ELISpot
assay. Positive peptide-specific IFNγ responses in vivo were
observed for 11 peptides, eight of which evoked responses in at
least 2/3 mice (Table 4). All 11 of these immunogenic peptides
were predicted to bind HLA-DR3, and all except one (p36) also
showed binding to DRB1∗0301 in vitro. Therefore, altogether
10/21 peptides both predicted and confirmed to bind HLA-
DR3 were immunogenic in vivo. None of the 13 peptides that
were predicted not to bind HLA-DR3 were immunogenic. An
odds ratio, calculated to determine the association of epitope
prediction and immunogenicity, showed a statistically significant
association for immunogenicity given an HLA-DR3 prediction
(Fisher’s exact test, p = 0.0229). No peptide-specific responses
were detected in mock-immunized mice that received vehicle
vaccine controls.
Selection of Coxiella-Exposed Human
Subjects for Epitope Antigenicity
Screening
The transgenic mouse study provided a snapshot of peptide-
specific immunogenicity for a single HLA class II allele. To assess
antigenicity across multiple HLA types and determine whether
the selected class I and II peptides are capable of recalling long-
lasting IFNγ memory responses, we next turned to a unique
cohort of individuals naturally exposed toC. burnetii. Subjects for
this study were recruited from a well-characterized population in
the village of Herpen in the Netherlands (48), which experienced
a high incidence of C. burnetii infection during the 2007–2010
Q fever outbreak. Recruited subjects were categorized based on
clinical Q fever history and recall responses to heat-killed C.
burnetii in a whole blood IFNγ release assay (IGRA) (Table 5).
Group A and B subjects had no clinical history of Q fever,
while group C individuals had recovered from an acute episode
of diagnosed Q fever. Group A controls had no IFNγ recall
responses to C. burnetii. Group B (past asymptomatic infection)
and group C (past symptomatic infection) subjects showed
varying degrees of IFNγ recall responses to C. burnetii (both
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TABLE 2 | HLA class II epitopes selected for immune reactivity screening.
ID Epitope Source antigen Predicted HLA II restrictions
CBU code UniProt ID Gene name
p1 SEQITLQTAEKVGLNVA CBU_1910 H7C7D7 com1 DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0701, DRB1*1101, DRB1*1301, DRB1*1501
p2 TPTFVIGNKALTKFGF CBU_1910 H7C7D7 com1 DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0801, DRB1*1101, DRB1*1301, DRB1*1501
p3 KDDILEAVANMSVMDV CBU_0229 P0C8S3 rplL DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0701, DRB1*0801, DRB1*1101,
DRB1*1301, DRB1*1501
p4 KIGVIKAIRTITGLGLKEA CBU_0229 P0C8S3 rplL DRB1*0101, DRB1*0401, DRB1*0701,
DRB1*0801, DRB1*1101, DRB1*1301, DRB1*1501
p5 LAQYRELEAFSQFAS CBU_1943 Q83AF7 atpA DRB1*0101, DRB1*0401, DRB1*0701,
DRB1*0801, DRB1*1101, DRB1*1501
p6 SHEVLHAMSRGVEVLA CBU_1718 P19421 groL DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0701, DRB1*0801, DRB1*1101, DRB1*1501
p7 SRAFLTANKNKPGVKT CBU_0630 P51752 mip DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0801, DRB1*1101, DRB1*1301, DRB1*1501
p8 IKGWQEALTRMKPGAIWEI CBU_0630 P51752 mip DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0701, DRB1*0801, DRB1*1101, DRB1*1501
p9 AIYFIGWYANLAHIKLGIS CBU_2065 Q83A45 DRB1*0101, DRB1*0401, DRB1*0701,
DRB1*0801, DRB1*1101, DRB1*1301, DRB1*1501
p10 EHTIVVNASASEAAALQ CBU_1943 Q83AF7 atpA DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0701, DRB1*0801, DRB1*1301, DRB1*1501
p11 PITKKQLKTMSNYEVIAK CBU_1869 Q83AL4 DRB1*0101, DRB1*0401, DRB1*0701,
DRB1*0801, DRB1*1101, DRB1*1301, DRB1*1501
p12 GKHFDGIKVLKLSPQNTI CBU_1869 Q83AL4 DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0701, DRB1*0801, DRB1*1101,
DRB1*1301, DRB1*1501
p13 FTFRSQDSRRVQEW CBU_1853 Q83AN0 GtrA family protein DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0701, DRB1*1101, DRB1*1301, DRB1*1501










p16 LKPFHFISSPTRDLQIA CBU_1716 Q83B06 gcvT DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0701, DRB1*0801, DRB1*1101,
DRB1*1301, DRB1*1501
p17 KIPVKIIKPPFVRRG CBU_1716 Q83B06 gcvT DRB1*0101, DRB1*0401, DRB1*0701,
DRB1*1101, DRB1*1301, DRB1*1501




p19 EAVYKGFTPLKAEDIAEA CBU_1513 Q83BJ5 short chain
dehydrogenase
DRB1*0101, DRB1*0401, DRB1*0701,
DRB1*0801, DRB1*1101, DRB1*1301, DRB1*1501
p20 AQPIIHRLSTGQNTNP CBU_1416 Q83BT6 repressor protein C2 DRB1*0101, DRB1*0401, DRB1*0701,
DRB1*0801, DRB1*1101, DRB1*1301, DRB1*1501
p21 IARYFMVNISQLIGEE CBU_1416 Q83BT6 repressor protein C2 DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0701, DRB1*0801, DRB1*1501
p22 RLGFMSFFTKAVVEALKRF CBU_1398 Q83BU7 sucB DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0701, DRB1*0801, DRB1*1101,
DRB1*1301, DRB1*1501
p23 REAVLFLVTIKELLEDP CBU_1398 Q83BU7 sucB DRB1*0301, DRB1*0401, DRB1*0701,
DRB1*0801, DRB1*1301
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TABLE 2 | Continued
ID Epitope Source antigen Predicted HLA II restrictions
CBU code UniProt ID Gene name
p25 SDMWQALLAGKSGVK CBU_0497 Q83E37 fabF DRB1*0101, DRB1*0401, DRB1*0701,
DRB1*0801, DRB1*1101, DRB1*1501




p27 RFDLSLMLNYPNSADRY CBU_1157 Q83CG1 DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0701, DRB1*0801, DRB1*1101,
DRB1*1301, DRB1*1501
p28 ISLLVFKNSHRVQLWAK CBU_1157 Q83CG1 DRB1*0101, DRB1*0301, DRB1*0701,
DRB1*0801, DRB1*1101, DRB1*1301, DRB1*1501
p29 VARVSRLKDNFVVLEISKGTEITVQ CBU_1143 Q83CH2 yajC DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0701, DRB1*0801, DRB1*1101, DRB1*1501
p30 GTEITVQKASIASVLPK CBU_1143 Q83CH2 yajC DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0701, DRB1*1101, DRB1*1301, DRB1*1501
p31 AENVLIIHNKTLAHRYLA CBU_0968 Q83CY3 phospholipase D DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0701, DRB1*0801, DRB1*1101,
DRB1*1301, DRB1*1501
p32 TGEIVKMINQAKQSIYVQG CBU_0968 Q83CY3 phospholipase D DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0801, DRB1*1101, DRB1*1301, DRB1*1501









p35 VFNITLQKVMAPELPVL CBU_0737 Q83DJ3 tig DRB1*0101, DRB1*0401, DRB1*0701,
DRB1*1101, DRB1*1301, DRB1*1501
p36 IDHLQQMTRQQVAMQTHK CBU_0737 Q83DJ3 tig DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0701, DRB1*0801, DRB1*1101,
DRB1*1301, DRB1*1501









p39 QELFVAQNKAMSDFM CBU_0612 Q83DT1 ompH DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0801, DRB1*1101, DRB1*1301, DRB1*1501
p40 QNAFQLQETIVSTEN CBU_0545 Q83DZ3 lemA DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0801, DRB1*1101, DRB1*1301, DRB1*1501
p41 LKDVVALRNQAQTAK CBU_0545 Q83DZ3 lemA DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0701, DRB1*0801, DRB1*1101, DRB1*1501
p42 DHAYKLAVSSTKSMT CBU_0497 Q83E37 fabF DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0701, DRB1*0801, DRB1*1101,
DRB1*1301, DRB1*1501
p43 NAGIIRNKLKIQATIN CBU_0383 Q83EE1 tag DRB1*0301, DRB1*0801, DRB1*1101, DRB1*1301
p44 GLSWLTILKKRNNYRDSFN CBU_0383 Q83EE1 tag DRB1*0301, DRB1*0801, DRB1*1101,
DRB1*1301, DRB1*1501
p45 GVAYTYNRANAGLPTNK CBU_0307 Q83EL2 outer membrane
protein
DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0701, DRB1*0801, DRB1*1101, DRB1*1501





p47 KAQLIQLKTHVTINAT CBU_0109 Q83F42 methionine-binding
protein
DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0701, DRB1*0801, DRB1*1101, DRB1*1301
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TABLE 2 | Continued
ID Epitope Source antigen Predicted HLA II restrictions
CBU code UniProt ID Gene name
p49 DQRITQLKNLNSNNSDSSNDN CBU_0092 Q83F57 ybgF DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0701, DRB1*0801, DRB1*1101,
DRB1*1301, DRB1*1501
p50 LRPVRYFTGVPSPVKTPE CBU_1200 Q9ZH99 icd DRB1*0101, DRB1*0401, DRB1*0701,
DRB1*1101, DRB1*1301, DRB1*1501
p < 0.0001 compared to group A controls by one-way ANOVA
with Holm-Šídák multiple comparisons test), with no significant
difference between the two groups (p = 0.9). HLA types were
sufficiently diverse within the total cohort to have all desired
HLA types represented in all three clinical groups (Tables S2, S3),
with the exception of HLA-DR8, which is underrepresented
particularly in group C, in accordance with this allele’s expected
low frequency in the Dutch population (42, 59, 60). Assessment
of the binding potential of all peptides with respect to the HLA
types of the 136 subjects in groups A-C showed no significant
differences across groups, with 75–82% of all class I peptides
and between 93 and 96% of all class II peptides predicted to be
recognized by each group.
Two partially overlapping subgroups of the total cohort were
selected based on a broad representation of HLA-A/HLA-B and
HLA-DR supertypes and allocated to HLA class I and II peptide
screening, respectively. The screening cohort for the 50 HLA
class II peptides consisted of 21 group A control donors (IGRA-,
no clinical disease), and 56 IGRA+ donors from groups B
(asymptomatic, n= 33) and C (symptomatic, n= 23) (Table S2).
The screening cohort for the 65 HLA class I peptides included
20 group A control donors (IGRA-, no clinical disease), and 57
IGRA+ donors from groups B (asymptomatic, n = 32) and C
(symptomatic, n = 25) (Table S3). Care was taken to maintain
a distribution of IGRA responses comparable to the total cohort
(Tables S2, S3).
Human Antigenic Responses to Predicted
HLA Class II Epitopes
Human antigenic T-cell IFNγ recall responses against the
predicted epitope clusters from C. burnetii were evaluated
ex vivo using freshly isolated peripheral blood mononuclear
cells (PBMCs) in a cultured ELISpot assay for detection of
central memory T-cells. A cultured ELISpot assay was used to
achieve high sensitivity for detecting low frequency antigen-
specific T-cell responses. Amongst the 3,843 assessments made
for the HLA class II peptides (50 peptides screened against 77
donors with some exceptions due to technical error or insufficient
cell numbers), 307 yielded positive responses [stimulation index
(SI)≥2, Figures S1, S2]. These antigenic responses covered 44/50
HLA class II peptides. Only six peptides were not recognized
by any subject (p9, p11, p34, p35, p40, and p49). For four of
these peptides, a second peptide from the same respective source
antigen induced recall responses by at least one IGRA+ subject.
Therefore, responses were detected to all but two (CBU_2065
and CBU_0092/YbgF) of the 29 source antigens fromwhich HLA
class II epitope clusters were predicted and screened.
The cumulative HLA class II peptide response per subject
was more frequent in IGRA+ compared to IGRA- subjects
(Figure 3A). The majority of IGRA- individuals recognized none
(10/21 donors) or only one or two peptides (8/21 donors). While
only 14% (3/21) of IGRA- group A individuals recognized three
or more peptides, this was true for 46% (26/56) IGRA+ group
B and C donors (Figure 3B). Amongst IGRA+ individuals,
there was a positive correlation between the cumulative number
of recognized peptides per donor, and the IFNγ responses to
whole heat-killed C. burnetii as assessed 12–17 months prior to
peptide screening (Figure 3C). Of note, all but one individual
that showed responses to three or more peptides had an IGRA
response of at least 250 pg/ml IFNγ in this standardized
assay (Figure 3D).
Of the 44 antigenic HLA class II peptides, 21 peptides were
recognized by >10% of all IGRA+ individuals (at least 6/56,
Figure 4A) and were hence considered highly antigenic. These
21 highly antigenic peptides accounted for 78.3% of all positive
peptide responses of IGRA+ individuals that reached a SI≥2
(220/281). A large proportion of these responses was well above
the cut-off of SI ≥2: Amongst responding IGRA+ individuals,
responses to 13 of these 21 peptides showed a median SI between
3.0 and 4.8 (Figure 4B), and for 11 of these peptides >10%
of all IGRA+ donors reached at least SI ≥3. Amongst IGRA-
control subjects group A, these peptides elicited either no recall
responses (11/21), or responses from only one or two individuals.
Only for a single peptide (p21) did the recall response frequency
reach a similar proportion in IGRA- (3/21; 14.3%) as in IGRA+
donors (8/56; 14.3%). Amongst the 21 highly antigenic peptides,
there were five source proteins that were represented by two
epitopes each (p14+p15, CBU_1835/protoporphyrinogen
oxidase; p18+p19, CBU_1513/short chain dehydrogenase;
p22+p23, CBU_1398/SucB, p37+p38, CBU_0718, p45+p46,
CBU_0307/outer membrane protein). Notably, not only were all
11 of the tgHLA-DR3 mice immunogenic peptides also antigenic
in at least one IGRA+ individual, but five of the tgHLA-DR3
immunogenic peptides were amongst the 21 highly reactive
peptides in the human cohort (p2, p14, p16, p22, p31).
Amongst IGRA+ donors, group C of past symptomatic
individuals had a higher proportion of high responders
(recognizing >10 peptides) and a smaller proportion of
non-responders to HLA class II epitope clusters than past
asymptomatic subjects (Group B, Figure 5A). However, the
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TABLE 3 | HLA class I epitopes selected for immune reactivity screening.
ID Sequence Source antigen Seta Primary HLA I Predicted HLA I restrictions
CBU code UniProt ID Gene name
p51 MVEEKYNYFY CBU_0885 Q83D57 T4SS A*0101 A*0101, A*0301, A*1101, A*6801,
B*3501, B*4403
p52 QSGWTIHHY CBU_1754 Q83AX3 T4SS A*0101 A*0101, A*0301, A*1101, B*3501, B*4403
p53 LTLLLNWVNY CBU_0077 Q83F71 Membrane-spanning
protein
T4SS A*0101 A*0101, A*0301, A*1101, A*6801,
B*3501, B*4403
p54 ETYNSINKY CBU_0794 Q83DE4 T4SS A*0101 A*0101, A*0301, A*1101, A*6801, B*4403
p55 HTYYLIGFLY CBU_1457 Q83BP6 Tetratricopeptide repeat
family protein
T4SS A*0101 A*0101, A*0301, A*1101, A*6801, B*4403
p56 YLLDRCPFL CBU_1754 Q83AX3 T4SS A*0201 A*0201, A*2402, B*0801
p57 RMYISFFPL CBU_1543 Q83BG5 T4SS A*0201 A*0201, A*2402, B*0702, B*0801,
B*2705, B*3501
p58 IMIDRLIEQL CBUA0006 Q45952 T4SS A*0201 A*0201, A*2402, B*0702, B*0801,
B*2705, B*3501
p59 ILDHFYSFL CBU_1556 Q83BF4 Membrane-spanning
protein
T4SS A*0201 A*0101, A*0201, A*0301, A*2402
p60 LLWHGVSTL CBU_0077 Q83F71 Membrane-spanning
protein
T4SS A*0201 A*0201, A*2402, B*0702, B*3501
p61 VLDCNYLSK CBU_0665 Q83DN3 T4SS A*0301 A*0101, A*0301, A*1101, A*6801
p62 ISYDRFTVGK CBU_2013 Q83A93 T4SS A*0301 A*0101, A*0301, A*1101, A*6801
p63 LLSTLCLYRK CBU_2078 Q83A33 Fic family protein T4SS A*0301 A*0101, A*0201, A*0301, A*1101, A*6801
p64 ATSNLIYKLK CBU_2078 Q83A33 Fic family protein T4SS A*0301 A*0101, A*0301, A*1101, A*6801
p65 GVDRFITYK CBU_0885 Q83D57 T4SS A*0301 A*0101, A*0301, A*1101, A*6801
p66 QYLQYLWPL CBU_1457 Q83BP6 Tetratricopeptide repeat
family protein
T4SS A*2402 A*2402, B*0801, B*4403
p67 TYRVLNYKDL CBU_0665 Q83DN3 T4SS A*2402 A*2402, B*0702
p68 LYDDEFKFL CBU_1639 Q83B74 T4SS A*2402 A*0101, A*2402
p69 SFVPKFFLTF CBU_2007 Q83A99 T4SS A*2402 A*2402, B*3501, B*4403
p70 GYHSITPYLF CBU_0773 Q83DG3 phnB T4SS A*2402 A*2402, B*4403
p71 SPHPRVNQF CBU_1556 Q83BF4 Membrane-spanning
protein
T4SS B*0702 B*0702, *08:02, B*3501, B*4403
p72 FPLGNQFLL CBU_1314 Q83C21 T4SS B*0702 A*0201, A*2402, B*0702, B*3501
p73 TPDFPQLFF CBU_0781 Q83DF6 Ankyrin repeat-containing
protein
T4SS B*0702 A*0101, A*2402, B*0702, B*3501
p74 LPRRHNFYNY CBUA0006 Q45952 T4SS B*0702 A*0101, A*0301, B*0702, B*3501
p75 KPLQVINRKY CBU_2007 Q83A99 T4SS B*0702 A*0101, B*0702, B*2705, B*3501, B*4403
p76 MEQKLWYPRL CBU_1677 Q83B41 T4SS B*4403 A*2402, B*0702, B*4403




T4SS B*4403 A*0201, A*2402, B*4403
p78 REMYSRRRMY CBU_1543 Q83BG5 T4SS B*4403 A*0101, B*2705, B*4403
p79 IERVFYYFPL CBU_1079 Q83CN2 T4SS B*4403 A*2402, B*0702, B*4403
p80 METPPQSPDF CBU_2052 Q83A58 T4SS B*4403 A*2402, B*0702, B*3501, B*4403
p81 GSDIIYHNY CBU_1398 Q83BU7 sucB S+ A*0101 A*0101, A*0301, A*1101, A*6801
p82 VSDATVAKWY CBU_1398 Q83BU7 sucB S+ A*0101 A*0101, A*0301, A*1101, A*6801
p83 KTEQDKLSY CBU_0630 P51752 mip S+ A*0101 A*0101, A*0301, A*1101, A*6801
p84 SLESGFTYY CBU_1260 Q83C69 OmpA-like
transmembrane domain
protein
S+ A*0101 A*0101, A*0301, A*1101, A*6801, B*4403
p85 FFEDFTHRY CBU_1835 Q83AP6 Protoporphyrinogen
oxidase
S+ A*0101 A*0101, A*0301, A*1101, A*2402,
A*6801, B*3501, B*4403
p86 VIDDLIVYRV CBU_1716 Q83B06 gcvT S+ A*0201 A*0101, A*0201
(Continued)
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TABLE 3 | Continued
ID Sequence Source antigen Seta Primary HLA I Predicted HLA I restrictions
CBU code UniProt ID Gene name
p87 FLIAVFARHL CBU_1967 Q83AD7 Multidrug resistance
protein D
S+ A*0201 A*0201, A*2402, B*0702
p88 MLWLPLLLIL CBU_1143 Q83CH2 yajC S+ A*0201 A*0201, A*2402, B*3501
p89 FLFFYSGLIL CBU_1967 Q83AD7 Multidrug resistance
protein D
S+ A*0201 A*0201, A*0301, A*2402
p90 NMFQHLPYL CBU_0109 Q83F42 Methionine-binding
protein
S+ A*0201 A*0201, A*2402, B*2705, B*3501
p91 KTFVYPMGLY CBU_0109 Q83F42 Methionine-binding
protein
S+ A*0301 A*0101, A*0301, A*1101, A*6801,
B*2705, B*4403
p92 ASFQNYLNDY CBU_0092 Q83F57 ybgF S+ A*0301 A*0101, A*0301, A*1101, A*6801,
B*2705, B*4403
p93 KLILFVYRY CBU_1853 Q83AN0 GtrA family protein S+ A*0301 A*0101, A*0301, A*1101, A*6801,
B*2705, B*3501, B*4403
p94 SLFANMNGHY CBU_0754 Q83DH7 Acriflavin resistance
protein
S+ A*0301 A*0101, A*0301, A*1101, A*6801, B*4403
p95 LSATFITSK CBU_1835 Q83AP6 Protoporphyrinogen
oxidase
S+ A*0301 A*0101, A*0301, A*1101, A*6801
p96 WYVVNNNYL CBU_1943 Q83AF7 atpA S+ A*2402 A*2402, B*3501, B*4403
p97 NFSDYIWHF CBU_0383 Q83EE1 tag S+ A*2402 A*0101, A*2402, B*4403
p98 IYDDRLLFEF CBU_0383 Q83EE1 tag S+ A*2402 A*0101, A*2402
p99 SFNGWIAYL CBU_0891 Q83D52 Membrane-associated
protein
S+ A*2402 A*2402, B*2705, B*4403
p100 TYRHNKKLL CBU_2065 Q83A45 S+ A*2402 A*2402, B*0702
p101 LPIDNFYAF CBU_1260 Q83C69 OmpA-like
transmembrane domain
protein
S+ B*0702 A*2402, B*0702, B*0801, B*3501
p102 LPRNRYRLVF CBU_1869 Q83AL4 S+ B*0702 A*2402, B*0702, B*0801, B*3501
p103 LPQKPWWKF CBU_2065 Q83A45 S+ B*0702 A*2402, B*0702, B*3501
p104 APVTHLFTV CBU_0307 Q83EL2 Outer membrane protein S+ B*0702 A*0201, B*0702, B*3501
p105 LPNHFAPQL CBU_0754 Q83DH7 Acriflavin resistance
protein
S+ B*0702 A*2402, B*0702, B*3501
p106 EEFVKTQSY CBU_1943 Q83AF7 atpA S+ B*4403 A*0101, B*4403
p107 MEVRDLLNSY CBU_0236 Q83ES6 tufA S+ B*4403 A*0101, B*4403
p108 GEEATAFLRY CBU_1716 Q83B06 gcvT S+ B*4403 A*0101, B*4403
p109 IEVVKKYMDY CBU_0545 Q83DZ3 lemA S+ B*4403 A*0101, B*4403
p110 NEIETATRY CBU_0664 Q81ZP4 Transposase S+ B*4403 A*0101, B*4403
p111 VTLVEFFDY CBU_1910 H7C7D7 com1 S+ A*0101 A*0101, A*0301, A*1101, A*6801, B*3501
p112 YYAFHDALL CBU_1910 H7C7D7 com1 S+ A*2402 A*2402
p113 KDIQSIVHHY CBU_1910 H7C7D7 com1 S+ B*4403 A*0101, B*2705, B*4403
p114 TPTFVIGNKA CBU_1910 H7C7D7 com1 S+ B*0702 B*0702, B*3501
p115 YLVNHPEVL CBU_1910 H7C7D7 com1 S+ A*0201 A*0201, A*2402
aAntigen set: substrates of the type IV secretion system (T4SS). Sero-reactive antigens (S+) based on antibody recognition in immune human sera.
two groups did not differ significantly in their cumulative
peptide response per subject (Figure 5B). When comparing
responses to individual peptides between group B and C,
there was again a trend that responses particularly to the
most antigenic peptides were more frequent amongst past
symptomatic donors and a number of peptides were recognized
only within this group by either a single (p3, p33) or multiple
donors (p1, p6, p10) (Figure 5C). There were some peptides,
however, that were recognized solely by past asymptomatic
subjects (p25, p42, and p43, 3/33 each; p13, p28, p29, and p33,
1/33 each).
Human Antigenic Responses to Predicted
HLA Class I Epitopes
Recall responses to the 65 HLA class I peptides were also
assessed using the cultured IFNγ ELISpot approach. In 4,794
assessments (65 peptides screened in 77 donors with some
exceptions due to technical error or insufficient cell numbers),
Frontiers in Immunology | www.frontiersin.org 12 February 2019 | Volume 10 | Article 207
Scholzen et al. Novel Promiscuous Q Fever Vaccine Epitopes
FIGURE 1 | HLA Class II Binding Assay Results. C. burnetii HLA class II epitope affinities for eight common DR alleles were assessed in competition binding assays.
Peptide binding strength was classified according to IC50 value in the following affinity categories: very high (<0.1µM), high (0.1–1µM), moderate (1–10µM), and low
(10–100µM). Epitopes with IC50 values >100µM or with no dose-dependent response were considered non-binders.
only 23 positive responses were detected (Figure S3). Four of
these positive responses came from IGRA- group A control
subjects. The remaining 19 responses were detected in IGRA+
subjects, with one individual recognizing 8 different peptides
(Figures S3, S4). Of the 15 HLA class I peptides that were
found to be antigenic in humans, ten peptides were recognized
by only a single donor each and only five HLA class I
peptides were recognized more than once: p53, p91, and p92
were each recognized by 2/57 donors, and two epitopes (p111
and p113) from com1 were recognized by 3/57 and 4/57
donors, respectively. Only two of the reactive peptides came
from the T4SS data set (p53, p54), the remaining 13 were
derived from sero-reactive source antigens. Albeit rare, HLA
class I peptide responses were clearly detectable, with nearly
half (11/23) of the positive responses reaching a stimulation
index (SI) of ≥3 (Figures S3, S4), and all responses were
consistent with predictions for primary or secondary HLA-A/B
allele binding.
Evaluation of Class I and Class II Epitopes
in Guinea Pig Model of Vaccine
Reactogenicity
Due to reactogenicity issues observed with the only Q fever
vaccine licensed for humans, all C. burnetii HLA class I and
class II peptides examined in this study were screened for
potential reactogenicity in a guinea pig model of exposure-
primed delayed-type hypersensitivity (55, 61), with the goal of
eliminating reactogenic peptides from further consideration for
inclusion in a vaccine. In contrast to reactogenicity mediated by
the whole cell phase I vaccine COXEVAC R©, no gross reactions
were noted at any of the negative control or peptide pool injection
sites (Figure S5). Mild lymphocytic inflammation (score = 1)
was noted in two HLA class II peptide pools; no overlap in
peptides was noted between the two pools and no other pools
with the same peptides showed histological changes. Therefore,
these reactions were not likely to be considered a reactogenic
response to C. burnetii peptides.
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FIGURE 2 | HLA Class I Binding Assay Results. C. burnetii HLA class I epitope affinities for six supertype HLA-A and HLA-B alleles were assessed in competition
binding assays. Peptide binding strength was classified according to IC50 value in the following categories: high affinity (<5µM), moderate affinity (5–50µM), and low
affinity (50–1,000µM). Epitopes with IC50 values >1,000µM or with no dose-dependent response were considered non-binders.
TABLE 4 | C. burnetii HLA class II epitope immunogenicity in tgHLA-DR3 mice.
Peptide ID No. of mice respondingd Mouse 1/3 Mouse 2/3 Mouse 3/3
SFUa SIb p-valuec SFUa SIb p-valuec SFUa SIb p-valuec
p2 2 120 6.63 0.0003 141 8.28 <0.0001 18 1.53 0.1384
p10 2 256 5.80 <0.0001 82 4.51 0.0043 43 2.00 0.0496
p14 2 157 7.94 0.0006 371 20.21 0.0001 11 1.42 0.0149
p16 1 180 8.94 0.0007 27 2.05 0.0060 19 1.94 0.0164
p23 2 69 2.30 0.0038 21 1.89 0.0372 63 2.47 0.0172
p28 2 63 3.76 0.0013 54 3.79 0.0094 41 2.63 0.0227
p31 1 0 0.88 0.1143 14 1.72 0.0621 84 4.32 0.0007
p32 2 64 3.82 0.0053 70 4.62 0.0103 28 2.11 0.0609
p36 2 52 3.44 0.0468 55 3.86 0.0193 0 0.86 0.2215
p41 1 87 5.06 0.0052 30 2.55 0.0433 0 0.98 0.3566
p43 3 135 4.88 0.0001 65 3.04 0.0013 116 4.48 0.0001
aAverage number of spot forming units (SFU) per million splenocytes from triplicate wells; the average number of SFU/million in medium only control wells was subtracted. Negative
values were assigned 0.
bStimulation index (SI) calculated as average number of SFUs in peptide stimulated wells over medium only control wells.
cSFUs in peptide stimulated wells from immunized mice compared to mock-immunized mice by Student’s t-test.
dMice are deemed responsive to a peptide if their SFU is >50 and if their SI is >2 and if their p-value is lower than 0.05.
DISCUSSION
In the present study, we aimed to identify HLA class I and
class II epitopes for inclusion in a non-reactogenic T-cell-
targeted vaccine to control C. burnetii infection and hence
prevent Q fever disease in humans. HLA binding competition
assays demonstrated a high accuracy of the immunoinformatic
predictions for HLA class I and class II recognition, and a murine
immunogenicity study demonstrated that half of the peptides
both predicted and shown to bind HLA-DR3 were also capable
of eliciting de novo responses in tgHLA-DR3 mice. Notably,
while responses to the 65 selected HLA class I epitopes were
barely detectable in PBMCs from individuals naturally exposed
to C. burnetii during the Dutch Q fever outbreak 7–10 years
prior to this study, 21 out of the 50 predicted HLA class II
epitope clusters recalled responses in 10–28% of those individuals
that also showed an ex vivo response to whole heat-killed C.
burnetii. We thereby demonstrate for the first time that natural
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TABLE 5 | Categorization of human study subjects.
Group N Age in years
(median, IQR)a




A (controls) 26 55 [47-57] 14 (54%) 3 [1–10.3] –
B (past asymptomatic) 73 54 [47-63] 47 (64%) 330 [168–660] –
C (past symptomatic) 37 54 [48-63] 20 (54%) 348 [180–717] +
aAt inclusion into the study in October 2015.
bAt inclusion into the study in October 2015, medium only background subtracted.
cEither formally notified or self-reported (48).
FIGURE 3 | Cumulative HLA class II peptide responses across clinical groups and in relation to IGRA. Data are shown for IGRA- and IGRA+ as the cumulative
peptide response (SI ≥2) per donor (A) or as the proportion of subjects recognizing 0, 1–2, 3–5, 6–10, or >10 peptides (B). (C) The cumulative number of peptides
recognized by individual IGRA+ subjects is plotted against their IGRA response to whole heat-killed C. burnetii and analyzed by Spearman correlation. (D) IGRA
responses are shown for IGRA+ individuals recognizing 0–2 or ≥3 peptides (cut-off SI≥2). Groups in (A,D) were compared by Mann-Whitney-test. Whisker-dot-plots
show the median and interquartile range (25 and 75th percentile) with whiskers extending from min to max values.
exposure of humans to C. burnetii induces long-lived responses
to immunodominant, promiscuous, and conserved HLA class
II T-cell epitope clusters. These peptide sequences are desirable
candidates for inclusion in a vaccine aiming to elicit sustained
T-cell memory in a broad and immunogenetically diverse human
population that can be boosted and recalled by natural exposure.
These long-lived epitope-specific T-cell responses are
consistent with previous studies in Q fever convalescent
individuals and recipients of the whole cell formalin-inactivated
phase I vaccine Q-VAX R©, which have consistently reported
a long-lived T-cell response to whole cell C. burnetii antigen.
The T-cell response, in this context, develops within 2 weeks
post-vaccination (62), is detectable for at least 8–10 years
following natural exposure or vaccination (63, 64) and in
some studies was found to be considerably more durable than
the mounted antibody response (62, 63). However, studies
investigating the specific antigen targets of the induced immune
response in humans have so far solely focused on antibodies
(20, 21, 23, 24, 26, 27, 29, 33, 65–71). T-cell antigen targets
have only been assessed in a limited number of murine studies
(18, 21, 22, 72), including one study that investigated T-cell
responses to recombinant C. burnetii proteins by ELISpot in
HLA-DR4 transgenic mice (21). T-cell antigen targets of murine
CD4 T-cells in these studies were all chosen based on antigen
recognition by human sera of Q fever exposed individuals
(18, 21, 22). While this B-cell antigen-guided screening approach
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FIGURE 4 | Highly antigenic HLA class II peptides identified by cultured IFNγ ELISpot assay. Data are shown as the number of individuals recognizing the 50 individual
peptides, depending on whether subjects are IGRA- (Group A, no clinical disease, n = 21; gray bars) or IGRA+ (Group B, asymptomatic; Group C, symptomatic;
n = 56; black bars). (A) Shows peptide responses reaching a SI ≥2. Bars extending over dotted lines indicate those peptides that were recognized by more than 10%
of IGRA- subjects (>2/21) or IGRA+ subjects (>5/56). (B) Shows the stimulation index for each positive response per subject for the 21 highly antigenic peptides
identified in (A). Whisker-dot-plots show the interquartile range (25 and 75th percentile) with whiskers extending from min to max values. Numbers indicate the median
SI per peptide for IGRA+ subjects.
for T-cell targets precludes identification of T-cell epitopes for
source antigens that do not elicit a dominant antibody response,
it has the advantage of significantly reducing and focusing the
number of antigens to be evaluated. In the present study, 44/50
HLA class II peptides (88%) from 27/29 selected sero-reactive
source antigens (93%) elicited T-cell recall responses from at
least one donor with a history of C. burnetii exposure during
the Dutch Q fever outbreak. This large hit rate for HLA class
II epitope clusters illustrated the feasibility of this approach to
focus on sero-reactive antigens for T-cell epitope prediction.
One major challenge when focusing a vaccine on individual
epitopes is to choose epitopes that are capable of eliciting
responses from a large part of the human population. Despite
the expected HLA diversity in this human cohort, 21/50 (42%)
of the screened HLA class II peptides, representing 16/29 source
antigens, were recognized by more than 10% of the subjects
exposed 7–10 years prior. In comparison, IFNγ recall responses
to H2 I-Ab-restricted C. burnetii epitopes were only detectable
for 17–26 and 5.3–6.8% of the predicted epitopes in inbred
C57BL/6 mice immediately following immunization with the
selected source antigens or whole cell antigen, respectively (18,
22). Of note, all but one of the antigens in the murine CD4
epitope vaccine study (18) were also amongst the HLA class
II source antigens in the present study, and one of the seven
vaccine epitope sequences (OmpA146–160), covered by p45 in
our peptide screening library, was one of the highly antigenic
peptides recognized by 7/56 (12.5%) of IGRA+ subjects. These
results validate the ability of the immunoinformatic algorithms
employed to predict promiscuous HLA class II epitopes for
humans. Moreover, the highly antigenic HLA class II epitopes
identified herein are not only promiscuous across HLA-DR
supertypes (76% predicted binding to 6 or more alleles) but are
also conserved across all C. burnetii genomes publicly available in
2015, as well as in the Dutch outbreak strain (39). Such conserved
immunodominant T-cell epitopes have also been found for
Mycobacterium tuberculosis (73–75), hepatitis C virus (76, 77),
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FIGURE 5 | Class II peptide antigenicity patterns in past asymptomatic and symptomatic, IGRA+ individuals. Data are shown as (A) the proportion of subjects
recognizing 0, 1–2, 3–5, 6–10, or >10 peptides for IGRA+ donors with past asymptomatic or symptomatic Q fever or (B) the cumulative peptide response (SI ≥2) per
donor. Groups are compared by Mann-Whitney-test. Whisker-dot-plots show the median, 25 and 75th percentile with whiskers extending from min to max values. (C)
Data are shown as the proportion of subjects recognizing the 50 individual peptides reaching a SI ≥2, depending on whether IGRA+ individuals were asymptomatic
(Group B, n = 32; gray bars) or symptomatic (Group C, n = 23; black bars) during the Q fever outbreak. Bars extending over dotted lines indicate those peptides that
were recognized by more than 10% of group B (>3/32) or group C subjects (>2/23).
and HIV (78, 79) and are interesting vaccine targets, since they
are likely under positive selection pressure and hence unlikely to
be subject to vaccine-induced immune evasion (73).
A somewhat unexpected finding of the present study was the
scarcity of detectable responses to the predicted HLA class I
epitopes in human subjects. Earlier studies indicated that human
CD8 T-cells contribute to C. burnetii-specific IFNγ production
(80), and in murine models CD8 T-cells appear to be more
critical than CD4 T-cells for resolving infection (15, 81). Using
a similar approach to the present study, a recent report identified
29 class I epitopes from T4SS substrates that conferred partial
protection in a murine vaccine-challenge study (72). One of these
29 was amongst the few HLA class I epitopes recognized by two
human donors (p92 from the tol-pal system protein YbgF). The
proportion of peptides recognized at least once in the human
cohort (15/65, 23%) was comparable to the recognition frequency
observed in the murine study (29/157, 18%), suggesting that
human HLA class I epitopes were predicted effectively in the
present study.
The much smaller frequency of HLA class I compared to
HLA class II responses could be due to a number of reasons.
Firstly, while HLA class II peptides are promiscuous epitope
clusters each containing 5–20 9-mers with various HLA-DR
binding motifs, HLA class I epitopes do not display this
promiscuity. Each of the 65 HLA class I peptides have, on
average, 0.4 binding motifs across the class I supertype alleles
modeled by EpiMatrix and represented in over 95% of the
global human population. This is in stark contrast to 1.36
binding motifs found, on average, for the 50 HLA class II
peptides across class II supertype alleles, representing a 3.4-fold
increase over the number of motifs for the HLA class I peptides.
The larger number of binding opportunities for HLA class II
peptides may thus contribute to the greater number of responses
they recalled.
Secondly, reports have shown that the TCR repertoire of
CD4 T-cells is estimated to be about five times greater than
the TCR repertoire of CD8 T-cells (82), suggesting that there
are more opportunities for CD4 T-cell reactivity. Finally, it
is also possible that circulating C. burnetii-specific CD8 T-
cells are less well detected than CD4 T-cells at such a late
time point (7–10 years) post-exposure, which would not be
unprecedented: following smallpox infection or vaccination,
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antigen-specific CD8 T-cells show a much faster contraction
to undetectable levels than do CD4 T-cells (83, 84). Similarly,
a significant contraction in Mycobacterium tuberculosis-specific
CD8 but not CD4 effector memory responses was reported
(85) as well as a significant decrease in total and antigen-
specific central memory CD8 T-cells (86). Of note, C. burnetii
epitope-specific murine CD8 T-cell responses were assessed only
10 days post-infection (72), and challenge experiments were
carried out no later than 28 days following vaccination or
transfer of infection-induced CD8 T-cells (15, 72). The most
obvious starting point for evaluating whether responses to a
common set of human HLA class I epitopes are induced by
natural exposure to C. burnetii would therefore be to screen
in much more recently exposed donors. In the absence of
another outbreak, inclusion of a sufficiently large cohort in
a reasonable time frame is, however, unlikely. Alternatively,
one could assess HLA class I epitope responses in individuals
that recently received the whole cell vaccine Q-VAX R©. This
would provide additional insights into the contribution of the
predicted epitopes to protection, which would also be valuable
for the identified highly reactive HLA class II epitope clusters.
Given that the vaccine is only licensed for use in Australia,
however, pursuit of such a study would be restricted to this
location. Finally, we cannot strictly conclude that the observed
HLA class II recall responses arise solely from CD4 T-cells and
not CD8 T-cells. Although rare, HLA class II-restricted CD8
T-cells have been identified in both mice (87) and humans
(88). Definitively addressing the relative responses would require
further experimentation with purified T-cell populations rather
than total PBMCs.
In the present study, we further compared epitope-specific
responses between C. burnetii exposed individuals with or
without a history of an acute clinical episode of Q fever. Although
responses tended to be more frequent in past symptomatic
donors and some peptides were recognized only by either past
symptomatic or asymptomatic individuals, these observations
are based on a relatively small number of responding subjects.
Moreover, none of the observed differences were striking enough
to suggest a significant difference in the quality of the induced
T-cell response between these two groups that would explain
why some individuals developed symptoms and others did not.
What would be of interest in future studies is to compare this
group of convalescent individuals with patients that developed
persistent infection with C. burnetii (chronic Q fever) (1, 89),
to identify those epitopes for which recognition may be crucial
to control and clear infection and hence might be lacking in
individuals with persistent infection. This would be analogous to
observations from herpes simplex virus vaccine research, where
distinct epitope-specific T-cell repertoires have been identified
for infected individuals that either successfully control infection
(asymptomatic) or not, leading to a proposed emphasis on so-
called “asymptomatic epitopes” (90).
The ultimate aim of the Q-VaxCelerate consortium is to
develop a non-reactogenic Q fever vaccine that could be
administered without screening for pre-exposure, especially in
an outbreak setting or when occupational hazard warrants
immediate broad-scale vaccination. Since none of the peptides
as such elicited a reactogenic response in the guinea pig model,
no peptides were eliminated from further consideration by
this screen. To minimize chances for reactogenicity of the
epitope vaccine in its final formulation, one delivery strategy
would be to use adenoviral vectors delivered intramuscularly.
In this way one could avoid the use of adjuvants that cause
localized inflammation at the injection site; such vectors
have had a good safety profile in human clinical trials and
have been shown to induce potent CD4 and CD8 T-cell
responses (91–93). Reactogenicity of the candidate vaccine
in its final formulation should then also include a parallel
evaluation of antigenicity in the same animal model as an
additional control.
In this study we focused on the identification of antigenic
and immunogenic T-cell epitopes and hence the cellular
component of the envisaged non-reactogenic multi-epitope
vaccine. However, we do not preclude the additional involvement
of a significant component of antibody-mediated protection
in vaccine design. While studies in murine models using
formalin-inactivated C. burnetii phase I vaccines (94) and of
the human whole cell vaccine Q-VAX R© (9) suggest a strong
contribution of antibodies to protection, how antibodies could
provide efficient protection against this intracellular pathogen
is not known. Specificity of the antibody response to Q-VAX R©
has only been analyzed by immunofluorescence assay against
whole cell C. burnetii, with the exception of a single study
assessing the targets of anti-sera from two Q-VAX R© vaccinees
by protein microarray (20). As an additional caveat, anti-
sera from patients with chronic Q fever recognizing phase I
antigens were shown to enhance C. burnetii infectivity and
replication in macrophages in vitro (95). Nevertheless, the
presence of C. burnetii-specific antibodies after both natural
infection and immunization (1, 9, 64), and the protective
role of these in animal models (12, 13, 94) warrant the
consideration of humoral responses in human vaccine design.
In this context, elicitation of epitope-specific antibody responses
has been described for a HLA class II multi-epitope DNA
vaccine (96). Further evaluation of a candidate multi-epitope
vaccine should thus also include assessment of humoral
responses. Additionally, vaccine optimization could involve
the inclusion of known immunogenic whole proteins (24)
or specifically selected sequences for (conformational) B-cell
epitopes, including a recently described lipopolysaccharide-
targeted peptide mimic (97).
In conclusion, we herein identify for the first time a set
of C. burnetii-specific HLA class II T-cell epitope clusters that
was computationally predicted and shown to bind a broad
range of HLA-DR types, elicit immunogenicity in tgHLA-DR3
mice and recalled long-lived memory responses in naturally
exposed individuals. Further research will focus on evaluating
the immunogenicity and protective efficacy of these desirable
candidates for a novel promiscuous multi-epitope-based Q fever
vaccine in animal models in an appropriate and non-reactogenic
formulation that can be transferred directly into clinical studies
in humans.
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